
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc. is poised for substantial revenue growth due to the high unmet medical need in the management of septic shock, particularly with the expected increase in demand for Giapreza as treatment guidelines are updated. The company has also reported significant sales growth for Xacduro, which is projected to reach a run rate of $95.3 million by 3Q25, reflecting strong commercial momentum and substantial y/y growth rates. Furthermore, the combination of durable patent protection and improvements in treatment safety profiles enhances Innoviva's prospects within the healthcare market.
Bears say
Innoviva Inc faces significant challenges in its healthcare portfolio, particularly within the critical care and infectious disease sectors, as evidenced by the high mortality rates associated with infections such as MRSA and CABP, which impact the financial viability of its products. The company's reliance on successful commercialization of its marketed products and new launches, such as ZEVTERA and zoliflodacin, is threatened by various risks, including potential declines in royalty revenues due to generic erosion and partnership uncertainties. Additionally, broader macroeconomic factors, such as tariff volatility, alongside the inherent risks related to antibiotic resistance, compound the negative outlook for Innoviva's financial performance and stock stability.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares